Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product

Patent metadata

Field	Value
Publication number	US-10435670-B2
Application number	US-201515303776-A
Country	US
Kind code	B2
Filing date	Apr 15, 2015
Priority date	Apr 15, 2014
Publication date	Oct 8, 2019
Grant date	Oct 8, 2019

Abstract

Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.

First claim

The invention claimed is:

1. A method for continuously inactivating a virus during manufacture of a biological product, the method comprising the steps of:
(1) combining:
(a) a composition comprising a biological product; and
(b) a composition comprising a virus-inactivation reagent, to obtain:
(c) a treatment composition having a predetermined property for inactivation of a virus;

(2) confirming that the treatment composition exhibits the predetermined property;
(3) transferring the treatment composition to a treatment vessel that comprises an inlet, an outlet, and a static mixer and having an internal volume, the inlet and the outlet being positioned at opposite ends of a major axis of the treatment vessel and the static mixer being internal to the treatment vessel along the major axis, and the transferring occurring at the inlet;
(4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows along the major axis at a predetermined rate and contacts the static mixer, the combination of the predetermined temperature and the predetermined rate being sufficient to cause inactivation of the virus in the treatment composition based on the predetermined property; and
(5) collecting the treatment composition from the treatment vessel at the outlet;
wherein steps (1) to (5) are carried out continuously,

wherein the predetermined property of the treatment composition comprises at least one of (a) a pH between 3.0 to 3.8 or (b) a detergent concentration between 0.05% and 10% (v/v), and wherein
the virus-inactivation reagent is an organic acid having a titratable group having a pKa between 2.3 to 4.2 and not having another titratable group having a pKa between 4.2 and 8.5, lactic acid, formic acid, ascorbic acid, or a combination thereof; and
the predetermined property of the treatment composition comprises a pH between 3.0 to 3.8, wherein the confirming of step (2) comprises at least one of:
(a) measuring conductivity of the treatment composition, wherein the composition comprising the virus-inactivation reagent further comprises a salt at a predetermined ratio to the virus-inactivation reagent and the conductivity indicates the concentration of the salt in the treatment composition;
(b) measuring an initial temperature of the treatment composition, wherein the initial temperature of the treatment composition is determined by a difference in temperature of the composition including the biological product and temperature of the composition including the virus-inactivation reagent and indicates the relative proportions of the composition including the biological product and the composition including the virus-inactivation reagent in the treatment composition;
(c) measuring a spectrophotometric characteristic of the treatment composition, wherein the composition comprising the virus-inactivation reagent further comprises a chromophoric compound at a predetermined ratio to the virus-inactivation reagent and the spectrophotometric characteristic indicates the concentration of the chromophoric compound in the treatment composition;
(d) measuring a spectroscopic characteristic of the treatment composition, wherein the composition comprising the biological product, as provided, comprises a pH-sensitive group and the spectroscopic characteristic indicates the pH of the treatment composition; or
(e) measuring a spectroscopic characteristic of the treatment composition, wherein a compound including a pH-sensitive group, that is not included in the composition including the biological product as provided, is subsequently added to the composition including the biological product, is included in the composition including the virus-inactivation reagent, and/or is otherwise added to the treatment composition, and the spectroscopic characteristic indicates the pH of the treatment composition.

2. The method of claim 1 , wherein:
the virus-inactivation reagent is an amino acid having a titratable group having a pKa between 2.3 to 4.2 and not having another titratable group having a pKa between 4.2 and 8.5, glycine, or a combination thereof; and
the predetermined property of the treatment composition comprises a pH between 3.0 to 3.8, wherein the confirming of step (2) comprises at least one of:
(a) measuring conductivity of the treatment composition, wherein the composition comprising the virus-inactivation reagent further comprises a salt at a predetermined ratio to the virus-inactivation reagent and the conductivity indicates the concentration of the salt in the treatment composition;
(b) measuring an initial temperature of the treatment composition, wherein the initial temperature of the treatment composition is determined by a difference in temperature of the composition including the biological product and temperature of the composition including the virus-inactivation reagent and indicates the relative proportions of the composition including the biological product and the composition including the virus-inactivation reagent in the treatment composition;
(c) measuring a spectrophotometric characteristic of the treatment composition, wherein the composition comprising the virus-inactivation reagent further comprises a chromophoric compound at a predetermined ratio to the virus-inactivation reagent and the spectrophotometric characteristic indicates the concentration of the chromophoric compound in the treatment composition;
(d) measuring a spectroscopic characteristic of the treatment composition, wherein the composition comprising the biological product, as provided, comprises a pH-sensitive group and the spectroscopic characteristic indicates the pH of the treatment composition; or
(e) measuring a spectroscopic characteristic of the treatment composition, wherein a compound including a pH-sensitive group, that is not included in the composition including the biological product as provided, is subsequently added to the composition including the biological product, is included in the composition including the virus-inactivation reagent, and/or is otherwise added to the treatment composition, and the spectroscopic characteristic indicates the pH of the treatment composition.

3. The method of claim 1 , wherein the combination of the predetermined temperature and the predetermined rate is sufficient to cause inactivation of the virus in the treatment composition by the virus-inactivation reagent during step (4) by a factor of at least 1×10 1 .

4. A method for continuously inactivating a virus during manufacture of a biological product, the method comprising the steps of:
(1) combining:
(a) a composition comprising a biological product; and
(b) a composition comprising a virus-inactivation reagent, to obtain:
(c) a treatment composition having a predetermined property for inactivation of a virus;

(2) confirming that the treatment composition exhibits the predetermined property;
(3) transferring the treatment composition to a treatment vessel that comprises an inlet, an outlet, and a static mixer and having an internal volume, the inlet and the outlet being positioned at opposite ends of a major axis of the treatment vessel and the static mixer being internal to the treatment vessel along the major axis, and the transferring occurring at the inlet;
(4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows along the major axis at a predetermined rate and contacts the static mixer, the combination of the predetermined temperature and the predetermined rate being sufficient to cause inactivation of the virus in the treatment composition based on the predetermined property; and
(5) collecting the treatment composition from the treatment vessel at the outlet;
wherein steps (1) to (5) ar

Assignees

• Boehringer Ingelheim Int

Inventors

• Coffman jonathan
• Goby Jeff
• Godfrey Scott
• Orozco Raquel
• Vogel Jens Holger

Classifications

• A61L2/16

  using chemical substances · CPC title

• A61L2103/05

  Living organisms or biological materials · CPC title

• A61L2/18 Primary

  Liquid substances · CPC title

• C12N2710/00063

  by chemical treatment · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title